Published online before print October 21, 2002, doi: 10.1161/01.HYP.0000039749.75068.F4
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2002;40:903.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
Racial Difference in the Activity of the Amiloride-Sensitive Epithelial Sodium Channel
From the Department of Medicine, Indiana University School of Medicine (J.H.P., R.A., G.J.E., S.N.), and the Veterans Administration Medical Center (J.H.P., R.A., S.N.), Indianapolis, Ind; and the Department of Public Health Sciences, Wake Forest University School of Medicine (W.T.A.), Winston-Salem, NC.
Correspondence to J. Howard Pratt, MD, 541 Clinical Drive, Indianapolis, IN 46202-5111. E-mail johpratt{at}iupui.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Compared with whites, blacks appear to retain additional sodium that suppresses secretion of renin and aldosterone. The epithelial sodium channel (ENaC) is an aldosterone-regulated site for sodium reabsorption. ENaC activity could be higher in blacks, contributing to sodium retention or, alternatively, lower because of reduced stimulation by aldosterone. To examine the level of ENaC activity in blacks relative to whites, blood pressure (BP) responses to amiloride (5 mg/d), an inhibitor of ENaC, were measured in 20 black and 25 white normotensive young people. After 1 week, systolic BP decreased by 3.0±9.2 (SD) and diastolic by 2.8±8.3 mm Hg in the whites, whereas systolic BP increased by 2.5±7.1 and diastolic by 3.8±8.0 mm Hg in the blacks; the racial difference in the BP response was significant for both systolic (P=0.034) and diastolic BP (P=0.010). As ENaC activity increases, renal secretion of potassium increases proportionately, and in a larger sample of subjects, the urinary potassium excretion rate was lower in the blacks (n=301) than in the whites (n=461): 3.2±0.1 versus 3.8±0.1 mmol/mmol creatinine (P=0.0001). The concentration of serum potassium was higher in the blacks (n=81) than in the whites (n=167): 4.36±0.05 versus 4.21±0.03 (P=0.012). In summary, a favorable BP response to amiloride in the whites as well as the evidence for greater retention of potassium in the blacks is consistent with blacks having less ENaC activity than whites. We suggest that increased sodium retention in blacks occurring at other nephron sites suppresses aldosterone secretion and in turn ENaC function.
Key Words: aldosterone • blacks • blood pressure • sodium • sodium channels
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
An increase in the renal reabsorption of sodium contributes to the risk of hypertension.1 Blacks retain more sodium than whites, as suggested by lower levels of plasma renin activity (PRA) in blacks2–5 and an increase in the likelihood for developing salt-sensitive hypertension.6 Where sodium retention in the kidney occurs in blacks is unknown, although one consideration has been the epithelial sodium channel (ENaC) in the cortical collecting duct, a highly regulated channel with known influences on sodium homeostasis.7 Several hypertensive syndromes stemming from single-gene mutations have as a final common mediator increased sodium reabsorption by an overactive ENaC.8 Indeed, mutations in ENaC itself can lead to a low-renin form of hypertension known as Liddle’s syndrome.9–12 We have previously reasoned that ENaC could be intrinsically more active in blacks, based on observations of a cohort of young people in whom the plasma level of aldosterone and the urinary excretion rate of aldosterone have consistently been found to be lower in the blacks than in the whites,13–15 suggestive of a more active ENaC resulting in sodium retention and secondary suppression of the renin-angiotensin-aldosterone axis. Aldosterone levels are, for example, very low in Liddle’s syndrome. Also, common molecular variations in ENaC that exist primarily in blacks have been shown to associate with hypertension and/or suppression of PRA and aldosterone levels.16,17
On the other hand, the suppressed levels of aldosterone that we observe in blacks could lower ENaC function since a principal action of aldosterone is to upregulate activity of the channel.18 If ENaC function is lower in blacks, it might indicate greater reabsorption of sodium at another site. In the present study, we addressed the question, is ENaC more or less active in blacks in comparison to whites? We explored the issue of a racial disparity in the level of ENaC function by treatment with amiloride, an inhibitor of ENaC, and comparing the blood pressure (BP) responses in blacks and whites. Subjects were from the cohort in which we had identified the lower aldosterone in blacks. In addition, since ENaC function plays an integral role in determining potassium homeostasis (sodium reabsorption by ENaC produces an electrical gradient favoring secretion of potassium), we also made measurements of potassium to further estimate the relative amounts of ENaC activity in blacks and whites.
Just as one can learn from single gene defects in family studies, so might one learn from comparisons of population groups with different susceptibilities to hypertension. A better definition of sites for increased sodium reabsorption in blacks could have important relevance to common forms of hypertension regardless of ethnicity.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
All participants were from a cohort that included school-age children and young adults who had been followed as part of studies of BP regulation.19 For the amiloride study, members of the cohort were sent letters inviting them to participate. For the studies in which potassium excretion rates and serum potassium levels were measured, we used samples that had been collected from members of the cohort who had agreed to provide an overnight urine sample and a blood sample. Each of the participants was healthy and had a normal BP; none were taking medication that might affect BP. The study was approved by the Indiana University/Purdue University of Indianapolis Committee on Protection of Human Subjects. Each subject, and when appropriate, a parent, gave informed consent.
Treatment With Amiloride
The subjects were admitted to the General Clinical Research Center (GCRC) the afternoon before measurements were made. They were fed an evening meal containing 10 mmol of sodium and 20 mmol of potassium. The following morning, BP was measured 3 times, with 1 to 2 minutes in between readings, using a mercury sphygmomanometer with subjects remaining recumbent. They were then fed breakfast, containing 5 mmol of sodium and 20 mmol of potassium. Blood samples were drawn for levels of renin activity and aldosterone while supine and after 1 hour of sitting followed by 1 hour of standing (7 and 9 AM samples) and potassium (7 AM). Then, as outpatients, the subjects took 5 mg amiloride per day for 1 week, after which they were readmitted to the GCRC, and the measurements made at baseline were repeated. Compliance with the treatment was assessed by pill counts.
Measurements of Potassium
Urine samples were collected overnight and serum samples collected in the morning for measurements of electrolytes.
Assay Procedures
Electrolytes were measured with a flame photometer (Instrumentation Laboratories), and urinary creatinine was measured with a Beckman-2 creatinine analyzer. Aldosterone was measured directly by radioimmunoassay with a kit from Diagnostic Products Corporation, and PRA was measured by radioimmunoassay with the Clinical Assays GammaCoat kit.
Statistical Analysis
Comparisons between blacks and whites for differences at baseline and differences in the changes before and after the administration of amiloride were made with the use of 2-sample t tests. A paired t test was used to make comparisons before and after the administration of amiloride. With respect to racial comparisons of serum potassium levels and urinary potassium excretion rates, a mixed-model ANOVA was used with subject random effects to adjust for the correlation between multiple measurements from some of the subjects.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Characteristics
The baseline characteristics of the 20 blacks and 25 whites who participated in the amiloride study are presented in Table 1. Age, body mass index (BMI, calculated as weight/height2 [kg/m2]), and proportion of girls were similar in the blacks and the whites. Systolic BP was 5 mm Hg higher in the whites (marginally significant at P=0.075), and diastolic BP was 3 mm Hg higher in the whites, a difference that was not significant (P=0.42). In the blacks, PRA was lower at 7 AM (P=0.040) and marginally lower at 9 AM (P=0.094); the plasma aldosterone was also marginally lower in the blacks both at 7 AM (P=0.076) and 9 AM (P=0.092). The serum potassium concentration was similar in this group of blacks and whites, as was the serum sodium concentration; urinary potassium and urinary sodium excretion rates were also similar in the blacks and the whites.
|
There were 301 blacks and 461 whites in whom the urinary excretion of potassium was measured. The mean ages were12.2±2.6 (SD) and 12.8±2.9 years in the blacks and whites, respectively, and the BMIs were 21.6±5.7 and 20.8±5.2 kg/m2 in the blacks and whites, respectively. The serum potassium concentration was measured in a subset of 81 blacks and 167 whites. The mean ages and BMIs in this subset of subjects were slightly higher in this group: 14.8±2.0 and 15.1±2.0 years and 25.0±5.8 and 21.8±4.1 kg/m2 in the blacks and whites, respectively.
Responses to Amiloride
Amiloride inhibited ENaC function, as evidenced by the increase in the levels of both PRA (P=0.005) and plasma aldosterone (P=0.0001) (for blacks and whites combined, both at 7 and 9 AM) (Figure 1). Serum potassium also significantly increased (for the blacks and the whites combined, P=0.0094) (Table 2). The increments in the blood levels of renin activity, aldosterone, and potassium were similar in the blacks and the whites (P>0.25). The plasma aldosterone increased more than PRA (level of aldosterone increased 3-fold after amiloride), most likely because of stimulation of aldosterone secretion by the increase in potassium and angiotensin II.20
|
|
Systolic and diastolic BP decreased in the whites but not in the blacks after treatment for 1 week with amiloride (Table 2). The racial differences in the BP responses were significant for both systolic (P=0.034) and diastolic BP (P=0.010). The weight change after treatment was not significantly different in the blacks and the whites (P=0.18).
Urinary Potassium Excretion and Serum Concentrations of Potassium
In a cross-sectional sampling of subjects from the same cohort, the urinary excretion of potassium was significantly lower in the blacks than in the whites (P<0.0001) (Table 3). In addition, the serum potassium concentration was significantly higher in the blacks than the whites (P=0.012). The racial difference in serum potassium was not the same in girls and boys: The potassium concentration was 4.40±0.07 in the 39 black girls and 4.16±0.05 mmol/L in the 78 white girls (P=0.0057); the potassium concentration was 4.32±0.06 in the 42 black boys and 4.25±0.04 mmol/L in the 89 white boys (P=0.40).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In the present study, a small dose of amiloride, an inhibitor of ENaC, reduced BP in the whites but not in the blacks—a difference in response between race groups that was significant. The results were consistent with the blacks having less ENaC activity to inhibit. In a larger sample of subjects, the urinary potassium excretion rate, determined in part by secretion of potassium at the collecting duct in response to sodium reabsorption by ENaC, was lower, and the serum potassium concentration was higher in the blacks than in the whites, also consistent with ENaC function being lower in the blacks. We suggest that in the blacks there was increased sodium retention at other sites that suppressed aldosterone levels, resulting in fewer ENaCs at the cell surface. In addition, with less sodium reaching the cortical collecting duct, there would be reduced numbers of sodium ions reabsorbed by ENaC, which would also lower potassium secretion.21
The racial difference in the BP response to amiloride, although significant, was modest. Conceivably, the levels after treatment reflected more a regression toward the mean (although not significant, the BPs at baseline were somewhat higher in the whites than in the blacks). Although this remains a possibility, we took precautions to limit extraneous influences on the BP. To begin with, subjects were admitted to an inpatient facility the day before with the BP measured the following morning while subjects were remaining supine; diet and level of activity were thus very similar at the baseline visit and the postamiloride visit. We administered a low dose of amiloride to minimize the chance of a nonspecific diuretic effect. Finally, the subjects who participated were young and normotensive, and thus we avoided the wider range of BP values that can occur in studies of older adults, especially those with hypertension.
Amiloride can also inhibit other sites of sodium transport but is much more inhibitory of ENaC. For example, the IC50 (µmol/L) of amiloride for ENaC has been reported to be 0.35, in comparison to 84 for the Na+/H+ exchanger, 1100 for the Na+/Ca2+ exchanger, and 1100 for Na+/K+ATPase.22 Using an HPLC method to quantify amiloride in several of the subjects, we found that the urinary levels were in the range of 2 µmol/L, below the level necessary for inhibition of the other sodium reabsorptive sites but a level that would inhibit ENaC. Amiloride could have a nonspecific diuretic effect that lowered BP more in the whites (there may have been, for example, greater consumption of sodium by the whites). However, this seems unlikely because the levels of PRA and aldosterone tended to be lower in the blacks, suggesting more sodium retention.
The lower urinary potassium excretion in blacks has been described previously by others23,24 as well as by our own group.13 It has been suggested that it results from a diet lower in potassium, although evidence for this was derived from studies carried out much earlier23,25,26 with possibly less relevance to patterns of intake today. Furthermore, it was never established that diet alone accounted for all the racial difference in potassium excretion. A lower excretion of potassium could also result from a reduction in Na+/K+ ATPase activity with increased sodium reabsorption by an alternative sodium transport mechanism. This seems unlikely, however, in that only a reduced ENaC activity could explain the lesser BP response to amiloride. The higher serum potassium in the blacks has not, to our knowledge, been described in adults. Previous studies showed either no racial difference or lower levels of serum potassium in blacks.5,27 Variations in serum potassium between groups could, of course, stem from differences in diet or in some instance from previous treatment with diuretics. Our black subjects could have consumed a diet that was richer in potassium, something we did not assess. None of our subjects had been exposed to diuretic therapy because none were hypertensive. If indeed the blacks were retaining additional potassium by a renal mechanism, it is unclear what mechanism exists for disposal of the excess. The fecal route is one possibility, but the transport of potassium by the colon is also ENaC-dependent,28 and if ENaC activity is reduced in blacks, then fecal secretion of potassium would also be expected to be less.
We have previously argued that ENaC activity could be higher in blacks than whites, based on the observation that the ratio of urinary aldosterone to urinary potassium was lower in blacks29 (in Liddle’s syndrome this ratio is extremely low10). If ENaC activity is indeed lower in blacks, as the current results indicate, then the reduced ratio in blacks is probably driven by the lower aldosterone secretion rate. The urinary aldosterone/potassium ratio may correctly predict ENaC activity but probably only at the extreme of increased sodium reabsorption by ENaC as in Liddle’s syndrome.
There may have been definite advantages to having performed the current study in subjects who were young and healthy. The racial difference in the response to amiloride and the difference in serum potassium concentration were both small and might easily have been missed in studies limited to adults, in which age or the presence of hypertension or its treatment can be confounding influences. We have consistently observed in our young cohort lower aldosterone levels in both plasma and urine samples from the black subjects.13,15 Comparisons in adults have not always shown a similar separation of aldosterone levels between the two race groups,30 although PRA was generally noted to be lower in black adults2–4 and in some instances the aldosterone level after stimulation with angiotensin II or with upright posture31 was lower in blacks than in whites.
An important aspect of the current findings is the strong implication of non-ENaC regions as sites in which blacks retain additional sodium. Several specific locations can be suggested (Figure 2.), beginning with the proximal tubule, where angiotensin II increases sodium reabsorption.32 The higher frequency in blacks of an angiotensinogen molecular variant (M235T) that leads to a higher concentration of angiotensinogen33,34 could promote intrarenal angiotensin II-stimulated sodium reabsorption in blacks more than in whites. A second potential site is the Na-K-2Cl cotransporter in the thick ascending limb of Henle. Here, sodium reabsorption is coupled to a reduced excretion of calcium. Lower calcium excretion rates have been consistently observed in blacks in comparison to whites,35–37 and thus an increase in the cotransporter’s level of activity could explain the greater reabsorption of both sodium and calcium in blacks. A third potential site is the thiazide-sensitive Na-Cl cotransporter in distal convoluted tubule. The familial syndrome of low-renin hyperkalemic hypertension known as pseudohypoaldosteronism type II (PHA II)38,39 is qualitatively similar to what we observe in blacks. It has been shown to result from mutations in serine/threonine kinases that presumably enhance the activity of the cotransporter.40 This site is further implicated by the fact that blacks typically respond more favorably to treatment with a thiazide diuretic.41 A contribution of a more active Na-Cl cotransporter would, however, be expected to be partial because hyperkalemia, a consistent phenotype in PHA II even in the absence of hypertension,42 does not occur in healthy blacks.
|
The current results do not rule out the possibility that ENaC function could be inappropriately increased in blacks in light of the positive sodium balance that may already exist. The findings suggest only that it is not ENaC alone that accounts for increased sodium retention in blacks. If greater sodium retention stems from early teleological selection pressures, then indeed all sites where sodium is reabsorbed may be more efficient in blacks.
Perspectives
Increased sodium retention by the kidney may underlie much of the risk for hypertension, but identification of the specific nephron sites involved has remained elusive. By comparing a group that on average retains more sodium (blacks) with a group that on average retains less sodium (whites), we found evidence for a difference in sodium reabsorption that was limited to a region proximal to ENaC. We, as well as others, have considered ENaC a strong candidate site for the increased sodium retention in blacks, and indeed, our strong interest in ENaC led to the current study. We were surprised at the outcome because we anticipated that amiloride would reduce BP more in the blacks. The lower aldosterone level in blacks can, however, easily explain the results. Do the findings diminish a role for ENaC? Obviously somewhat, but ENaC could still play an important role, participating with other sites.
|
Acknowledgments |
|---|
This study was supported by National Institutes of Health grants R01-HL-35795, RO1-HL67360, and M01-RR00750 and a Merit Review grant from the US Department of Veterans Affairs. We are grateful to Mary Anne Wagner for excellent technical assistance.
Received May 28, 2002; first decision July 30, 2002; accepted September 16, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Guyton AC, Coleman TG. Long-term regulation of the circulation: interrelationships with body fluid volumes.In: Reeve EB, Guyton AC, eds. Physical Bases of Circulatory Transport: Regulation and Exchange. Philadelphia, Pa: WB Saunders Co Inc; 1967: 179–201.
2. Helmer OM. The renin-angiotensin system and its relation to hypertension. Prog Cardiovasc Dis. 1965; 8: 117–128.[CrossRef][Medline] [Order article via Infotrieve]
3. Channick BJ, Adlin EV, Marks AD. Suppressed plasma renin activity in hypertension. Arch Intern Med. 1969; 123: 131–140.
4. Kotchen TA, Guthrie GPJ, Cottrill CM, McKean HE, Kotchen JM. Low renin-aldosterone in "prehypertensive" young adults. J Clin Endocrinol Metab. 1982; 54: 808–814.
5. El Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, Hamet P, Pausova Z, Gaudet D, Gossard F, Kotchen TA. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension. 2001; 37: 845–850.
6. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996; 27: 481–490.
7. Horisberge J-D, Canessa C, Rossier BC. The epithelial sodium channel: recent developments. Cell Physiol Biochem. 1993; 3: 283–294.
8. Lifton RP. Molecular genetics of human blood pressure variation. Science. 1996; 272: 676–680.[Abstract]
9. Liddle GW, Bledsoe T, Coppage WS Jr. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians. 1963; 76: 199–213.
10. Bortero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle’s syndrome revisited: a disorder of sodium reabsorption in the distal tubule. N Engl J Med. 1994; 330: 178–181.
11. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW. Liddle’s syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994; 79: 407–414.[CrossRef][Medline] [Order article via Infotrieve]
12. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton RP. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet. 1995; 11: 76–82.[CrossRef][Medline] [Order article via Infotrieve]
13. Pratt JH, Jones JJ, Miller JZ, Wagner MA, Fineberg NS. Racial differences in aldosterone excretion and plasma aldosterone concentrations in children. N Engl J Med. 1989; 321: 1152–1157.[Abstract]
14. Bloem LJ, Manatunga AK, Pratt JH. Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension. 1996; 27: 62–66.
15. Pratt JH, Manatunga AK, Bloem LJ, Wei L. Racial differences in aldosterone excretion: a longitudinal study in children. J Clin Endocrinol Metab. 1993; 77: 1512–1515.[Abstract]
16. Baker EH, Dong YB, Sagnella GA, Roghwell M, Onnipinla AK, Markandu ND, Cappuccio FP, Cook DG, Persu A, Corvol P, Jeunemaitre X, Carter ND, MacGregor GA. Association of hypertension with T594 M mutation in ß subunit of epithelial sodium channels in black people resident in London. Lancet. 1998; 351: 1388–1392.[CrossRef][Medline] [Order article via Infotrieve]
17. Ambrosius WT, Bloem LJ, Zhou L, Rebhun JF, Snyder PM, Wagner MA, Guo C, Pratt JH. Genetic variants in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension. Hypertension. 1999; 34: 631–637.
18. Asher C, Wald H, Rossier BC, Garty H. Aldosterone-induced increase in the abundance of Na+ channel subunits. Am J Physiol. 1996; 271: C605–C611.[Medline] [Order article via Infotrieve]
19. Manatunga AK, Jones JJ, Pratt JH. Longitudinal assessment of blood pressures in black and white children. Hypertension. 1993; 22: 84–89.
20. Pratt JH. Role of angiotensin II in potassium-mediated stimulation of aldosterone secretion in the dog. J Clin Invest. 1982; 70: 667–672.[Medline] [Order article via Infotrieve]
21. Stokes JB. Potassium secretion by cortical collecting tubule: relation to sodium absorption, luminal sodium concentration, and transepithelial voltage. Am J Physiol. 1981; 241: F395–F402.[Medline] [Order article via Infotrieve]
22. Kleyman TR, Cragoe EJ Jr. Cation transport probes: the amiloride series. Methods Enzymol. 1990; 191: 739–755.[Medline] [Order article via Infotrieve]
23. Berenson GS, Voors AW, Dalferes ER, Jr, Webber LS, Shuler SE. Creatinine clearance, electrolytes, and plasma renin activity related to the blood pressure of white and black children-the Bogalusa heart study. J Lab Clin Med. 1979; 93: 535–548.[Medline] [Order article via Infotrieve]
24. Watson RL, Langford HG, Abernethy J, Barnes TY, Watson MJ. Urinary electrolytes, body weight, and blood pressure: pooled cross-sectional results among four groups of adolescent females. Hypertension. 1980; 2 (suppl I): I-93–I-98.
25. Grim CE, Luft FC, Miller JZ, Meneely GR, Battarbee HD, Hames CG, Dahl LK. Racial differences in blood pressure in Evans County, Georgia: relationship to sodium and potassium intake and plasma renin activity. J Chron Dis. 1979; 33: 87–94.
26. Frisancho AR, Leonard WR, Bollettino LA. Blood pressure in blacks and whites and its relationship to dietary sodium and potassium intake. J Chron Dis. 1984; 37: 515–519.[CrossRef][Medline] [Order article via Infotrieve]
27. Luft FC, Weinberger MH, Grim CE, Fineberg NS. Effects of volume expansion and contraction on potassium homeostasis in normal and hypertensive humans. J Am Coll Nutr. 1986; 5: 357–369.[Abstract]
28. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev. 2002; 82: 245–289.
29. Ambrosius WT, Bloem LJ, Zhou L, Rebhun JF, Snyder PM, Wagner MA, Guo C, Pratt JH. Genetic variants in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension. Hypertension. 1999; 34: 631–637.
30. Gomez-Sanchez CE, Holland OB. Urinary tetrahydroaldosterone and aldosterone-18-glucuronide excretion in white and black normal subjects and hypertensive patients. J Clin Endocrinol Metab. 1981; 52: 214–219.
31. Fisher ND, Gleason RE, Moore TJ, Williams GH, Hollenberg NK. Regulation of aldosterone secretion in hypertensive blacks. Hypertension. 1994; 23: 179–184.
32. Navar LG. The kidney in blood pressure regulation and development of hypertension. Med Clin North Am. 1997; 81: 1165–1198.[CrossRef][Medline] [Order article via Infotrieve]
33. Jeunemaitre X, Soubrier F, Kotelevtev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel J-M, Corvol P. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992; 71: 169–180.[CrossRef][Medline] [Order article via Infotrieve]
34. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest. 1995; 95: 948–953.[Medline] [Order article via Infotrieve]
35. Abrams SA, O’Brien KO, Liang LK, Stuff JE. Differences in calcium absorption and kinetics between black and white girls aged 5–16 years. J Bone Miner Res. 1995; 10: 829–833.[Medline] [Order article via Infotrieve]
36. Seifert-Mclean CM, Cromer BA, Mosher G, Mahan JD. Urinary calcium excretion in healthy adolescents. J Adolesc Health Care. 1989; 10: 300–304.[CrossRef][Medline] [Order article via Infotrieve]
37. Pratt JH, Manatunga AK, Peacock M. A comparison of the urinary excretion of bone resorptive products in white and black children. J Lab Clin Med. 1996; 127: 67–70.[CrossRef][Medline] [Order article via Infotrieve]
38. Paver WKA, Pauline GJ. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust. 1964: 305–306.
39. Gordon RD, Hodsman GP. The syndrome of hypertension and hyperkalaemia without renal failure: long term correction by thiazide diuretic. Scott Med J. 1986; 31: 43–44.[Medline] [Order article via Infotrieve]
40. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP. Human hypertension caused by mutations in WNK kinases. Science. 2001; 293: 1107–1112.
41. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993; 328: 914–921.
42. Mayan H, Vered I, Mouallem M, Tzadok-Witkon M, Pauzner R, Farfel Z. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab. 2002; 87: 3248–3254.
This article has been cited by other articles:
 |
|
 |
|
  T.-Y. Chun, L. Bankir, G. J. Eckert, D. G. Bichet, C. Saha, S.-A. Zaidi, M. A. Wagner, and J. H. Pratt Ethnic Differences in Renal Responses to Furosemide Hypertension, August 1, 2008; 52(2): 241 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Burnier Ethnic Differences in Renal Handling of Water and Solutes in Hypertension Hypertension, August 1, 2008; 52(2): 203 - 204. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Klevay, J. D. Bogden, M. Aladjem, H. H. Sandstead, F. W. Kemp, W. Li, J. Skurnick, and A. Aviv Renal And Gastrointestinal Potassium Excretion In Humans: New Insight Based On New Data And Review And Analysis Of Published Studies J. Am. Coll. Nutr., April 1, 2007; 26(2): 103 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bankir, J. Perucca, and M. H. Weinberger Ethnic Differences in Urine Concentration: Possible Relationship to Blood Pressure Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 304 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sachdeva and A. B. Weder Nocturnal Sodium Excretion, Blood Pressure Dipping, and Sodium Sensitivity Hypertension, October 1, 2006; 48(4): 527 - 533. [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Pratt Central Role for ENaC in Development of Hypertension J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3154 - 3159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Warnock and B. C. Rossier Renal Sodium Handling: The Role of the Epithelial Sodium Channel J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3151 - 3153. [Full Text] [PDF]
|
|
|
|
|
|
C. Saha, G. J. Eckert, W. T. Ambrosius, T.-Y. Chun, M. A. Wagner, Q. Zhao, and J. H. Pratt Improvement in Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension Hypertension, September 1, 2005; 46(3): 481 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Warnock and P. D. Bell Improvement of Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension Hypertension, September 1, 2005; 46(3): 469 - 470. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Meneton, X. Jeunemaitre, H. E. de Wardener, and G. A. Macgregor Links Between Dietary Salt Intake, Renal Salt Handling, Blood Pressure, and Cardiovascular Diseases Physiol Rev, April 1, 2005; 85(2): 679 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kimura, X. Lu, J. Skurnick, G. Awad, J. Bogden, F. Kemp, and A. Aviv Potassium Chloride Supplementation Diminishes Platelet Reactivity in Humans Hypertension, December 1, 2004; 44(6): 969 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Weinberger More on the Sodium Saga Hypertension, November 1, 2004; 44(5): 609 - 611. [Full Text] [PDF]
|
|
|
|
|
|
A. Aviv, N. K. Hollenberg, and A. Weder Urinary Potassium Excretion and Sodium Sensitivity in Blacks Hypertension, April 1, 2004; 43(4): 707 - 713. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||